(NASDAQ: ZYME) Zymeworks's forecast annual revenue growth rate of 25.86% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.37%, and while it is forecast to beat the US market's average forecast revenue growth rate of 14.21%.
Zymeworks's revenue in 2026 is $105,965,000.On average, 14 Wall Street analysts forecast ZYME's revenue for 2026 to be $21,891,833,342, with the lowest ZYME revenue forecast at $6,768,812,680, and the highest ZYME revenue forecast at $29,018,257,866. On average, 13 Wall Street analysts forecast ZYME's revenue for 2027 to be $14,607,584,658, with the lowest ZYME revenue forecast at $6,071,067,648, and the highest ZYME revenue forecast at $26,275,509,982.
In 2028, ZYME is forecast to generate $15,580,341,975 in revenue, with the lowest revenue forecast at $8,568,966,837 and the highest revenue forecast at $23,463,437,467.